sterna biologicals wins second place in Science4Life Venture Cup contest 2007
More than 200 start-up companies and teams of founders attended this year´s contest for the best ideas and concepts in bringing innovative products and services to the marketplace. 47 detailed business plans entered the final round and were evaluated by scientific and business experts in the field. The five best-ranked teams were invited to attend a 4 days high-class business founder workshop at the end of which they presented their business concepts in front of a jury with distinguished members from the fields of science, business and finance.
sterna biologicals is delighted that the company´s plan to develop DNAzymes as 3rd generation of antisense drugs for the treatment of chronic inflammatory diseases has been highly appreciated and honoured by the experts and the jury. Holger Garn, the Chief Executive Officer of sterna biologicals commented: "We are very honoured that our company receives such a highly distinguished award, which recognizes the importance of addressing key targets at the most earliest stage of the disease development. This success, however, was also made possible by the professional assistance by Tytonis and its network partners Apis Pharma and TransformRx."
Meistgelesene News
Organisationen
Weitere News aus dem Ressort Wirtschaft & Finanzen
Holen Sie sich die Life-Science-Branche in Ihren Posteingang
Mit dem Absenden des Formulars willigen Sie ein, dass Ihnen die LUMITOS AG den oder die oben ausgewählten Newsletter per E-Mail zusendet. Ihre Daten werden nicht an Dritte weitergegeben. Die Speicherung und Verarbeitung Ihrer Daten durch die LUMITOS AG erfolgt auf Basis unserer Datenschutzerklärung. LUMITOS darf Sie zum Zwecke der Werbung oder der Markt- und Meinungsforschung per E-Mail kontaktieren. Ihre Einwilligung können Sie jederzeit ohne Angabe von Gründen gegenüber der LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin oder per E-Mail unter widerruf@lumitos.com mit Wirkung für die Zukunft widerrufen. Zudem ist in jeder E-Mail ein Link zur Abbestellung des entsprechenden Newsletters enthalten.